Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

PharmacoEconomics - 1 Mar 2013

Frank Martin, Mittendorf Thomas

Abstract excerpt

BACKGROUND: Metastatic colorectal cancer (mCRC) imposes a substantial health burden on individual patients and society. Furthermore, rising costs in oncology cause a growing concern about reimbursement for innovations in this sector. The promise of pharmacogenomic profiling and related stratified therapies in mCRC is to improve treatment efficacy and potentially save costs. Among other examples, the commonly used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Health Care Costs

Share to Neoplasm Metastasis

Share to Pharmacogenetics

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 23338963
DOI: 10.1007/s40273-012-0017-2

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.PMID 23338963Read ↗

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.Semantic proximity Read ↗

Costs and effectiveness of genomic testing in the management of colorectal cancer.Semantic proximity Read ↗

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.Semantic proximity Read ↗

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentSemantic proximity Read ↗

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.Semantic proximity Read ↗

Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework.Semantic proximity Read ↗

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Semantic proximity Read ↗

Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile.Semantic proximity Read ↗

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Semantic proximity Read ↗

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

How Are We Evaluating the Cost-Effectiveness of Companion Biomarkers for Targeted Cancer Therapies? A Systematic ReviewSemantic proximity Read ↗

The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.